PHARMACEUTICAL LAW

Jalsovszky offers comprehensive legal services to international pharmaceutical companies, biotechnology firms, medical device manufacturers, and life sciences organizations operating in the Hungarian market. Our dedicated pharma practice Hungary team combines deep regulatory expertise with practical business understanding to navigate the complex landscape of Hungarian and European Union pharmaceutical regulations.

The Hungarian pharmaceutical market presents unique opportunities and challenges for international companies. As a member state of the European Union, Hungary operates within the framework of EU pharmaceutical directives while maintaining specific national requirements through the National Centre for Public Health and Pharmacy (NNGYK) and the National Health Insurance Fund (NEAK). Our pharmaceutical lawyers provide strategic counsel on all aspects of the pharmaceutical industry lifecycle, from initial market authorization through commercialization, compliance, and dispute resolution.

Understanding the interplay between EU harmonized regulations and Hungarian national law is essential for successful market entry and sustained commercial operations. Our pharmaceutical law Hungary practice helps clients optimize their regulatory strategies, minimize time to market, and maintain ongoing compliance with evolving legal requirements. We serve as trusted advisors who understand not only legal technicalities but also the commercial realities of pharmaceutical business operations.

Obtaining marketing authorization in Hungary requires meticulous preparation and strategic engagement with the National Centre for Public Health and Pharmacy (NNGYK). Our pharmaceutical lawyers guide clients through the entire authorization process for innovative pharmaceuticals, generics, biosimilars, and medical devices. We coordinate with regulatory authorities, and ensure compliance with both Hungarian national requirements and EU directives.

For companies developing innovative pharmaceuticals, we provide counsel on regulatory data protection strategies, helping maximize the commercial value of proprietary clinical and pre-clinical data. Our team advises on optimal pathways for obtaining orphan drug designations, which can provide significant regulatory and commercial advantages in the Hungarian market.

Our expertise extends to generics and biosimilars, where we navigate the specific regulatory requirements for demonstrating bioequivalence and biosimilarity. We understand the nuanced differences in regulatory pathways and help clients avoid common pitfalls that can delay market entry.

Hungary has become an increasingly attractive location for clinical trials due to its robust healthcare infrastructure and experienced patient populations. Our pharma practice Hungary team provides comprehensive legal support throughout the clinical trial lifecycle, including protocol review, ethics committee submissions, and regulatory authority interactions.

We draft and negotiate clinical trial agreements with research sites, contract research organizations, and academic institutions. Our pharmaceutical lawyers ensure that informed patient consent forms meet all legal requirements while remaining comprehensible to study participants. We advise on data protection compliance, patient privacy, and the complex intersection of clinical research regulations with GDPR requirements.

For sponsors conducting multi-country trials, we coordinate regulatory submissions and help navigate Hungary's specific requirements for adverse effect reporting and pharmacovigilance obligations during the investigational phase.

The Hungarian pharmaceutical industry operates under strict transparency requirements that mandate disclosure of transfers of value to healthcare professionals (HCPs) and healthcare organizations (HCOs). Our pharmaceutical lawyers provide practical guidance on navigating these transparency obligations, helping companies design compliant interaction models with the medical community.

We advise on fair market value assessments for consulting agreements, advisory boards, speaking engagements, and educational grants. Our team helps structure HCP and HCO interactions that deliver legitimate value while meeting all regulatory requirements. We conduct compliance reviews of existing arrangements and provide training to commercial teams on permissible interactions under Hungarian law.

For companies establishing operations in Hungary, we develop comprehensive transparency compliance programs that integrate with global compliance frameworks while addressing local specificities.

Operating a compliant commercial organization in Hungary requires careful attention to regulations governing sales representatives, promotional activities, and market access strategies. Our pharmaceutical lawyers advise on employment structures for sales teams, ensuring proper licensing and registration of sales representatives with NNGYK.

We review and approve promotional materials, including labelling for pharmaceutical products, to ensure compliance with Hungarian advertising regulations. Our team provides guidance on permissible claims, comparative advertising, and the distinction between prescription and OTC product promotion.

For promotional samples, we advise on distribution limits, documentation requirements, and controls necessary to prevent diversion. We help companies implement systems that balance commercial objectives with regulatory compliance.

Achieving favorable reimbursement status is critical for commercial success in Hungary's price-controlled pharmaceutical market. Our pharma practice Hungary team guides companies through the National Health Insurance Fund (NEAK) reimbursement application process, including price negotiations and health technology assessment submissions.

We advise on optimal reimbursement strategies for innovative pharmaceuticals, including considerations around reference pricing, external price referencing, and value-based agreements. For generics and biosimilars, we help navigate specific reimbursement pathways and advise on price positioning relative to reference products.

Our pharmaceutical lawyers represent clients in reimbursement appeals and administrative proceedings when initial applications are denied or pricing decisions are unfavorable. We maintain active relationships with key stakeholders in the reimbursement ecosystem.

Beyond pharmaceuticals, our pharmaceutical law Hungary expertise extends to medical devices, dietary supplements, and other life sciences products. We advise on the classification of borderline products, helping companies determine the appropriate regulatory pathway under Hungarian and EU law.

For medical devices, we provide guidance on conformity assessment procedures, notified body selection, and post-market surveillance obligations. Our team stays current with the evolving regulatory landscape, including implementation of the Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).

For dietary supplements and food supplements, we advise on permissible health claims, labelling requirements, and notification procedures with Hungarian authorities. We help companies navigate the complex boundary between pharmaceutical products and dietary supplements.

Maintaining marketing authorization requires ongoing pharmacovigilance and compliance with post-market obligations. Our pharmaceutical lawyers advise on pharmacovigilance system establishment, including qualified person requirements, safety database maintenance, and periodic safety update report submissions.

We provide guidance on adverse effect reporting timelines and procedures, helping companies meet expedited reporting obligations for serious adverse events. When safety concerns arise, we coordinate with regulatory authorities and advise on communication strategies, labelling updates, and potential market withdrawals.

Our team also advises on patient support programs, helping structure initiatives that provide genuine value to patients while meeting all legal and ethical requirements. We ensure these programs comply with transparency obligations and do not constitute improper inducements under Hungarian law.

Establishing effective distribution channels in Hungary requires carefully structured legal relationships with local partners. Our pharmaceutical lawyers draft and negotiate distribution agreements, supply agreements, and commercial contracts that protect our clients' interests while ensuring compliance with Hungarian competition law and pharmaceutical regulations.

We advise on exclusive and non-exclusive distribution models, territorial restrictions, and performance obligations. For companies choosing to work with local distributors, we ensure contracts address critical pharmaceutical-specific issues including product recall procedures, pharmacovigilance responsibilities, and regulatory liaison obligations.

Our team also negotiates manufacturing and supply agreements for companies producing pharmaceuticals in Hungary or sourcing products for distribution elsewhere in the European Union. We structure agreements that allocate regulatory responsibilities appropriately and establish clear protocols for quality issues, supply interruptions, and regulatory changes.

The Hungarian pharmaceutical pricing system involves complex interactions between manufacturers, the National Health Insurance Fund, and regulatory authorities. Our pharma practice Hungary team advises on pricing strategies from initial reimbursement applications through price revision procedures and mandatory price reductions.

We guide companies through the external price referencing system, helping identify optimal launch sequences across European markets to maximize Hungarian pricing outcomes. For innovative pharmaceuticals, we advise on value demonstration strategies and health economic assessments that support premium pricing positions.

When pricing disputes arise, our pharmaceutical lawyers represent clients in administrative proceedings and negotiations with NEAK. We also advise on legally compliant approaches to managed entry agreements, patient access schemes, and other innovative pricing arrangements that are gaining traction in Hungary's evolving reimbursement landscape.

Protecting intellectual property rights is fundamental to pharmaceutical business success. Our pharmaceutical law Hungary practice advises on patent strategies, supplementary protection certificates, and regulatory data protection to maximize the commercial lifecycle of pharmaceutical products.

We counsel on data exclusivity periods for innovative pharmaceuticals, helping companies understand and leverage the eight-year data protection and ten-year market protection available under EU law as implemented in Hungary. For generics and biosimilars, we advise on patent landscape assessments and strategies for market entry that minimize intellectual property risks.

Our team coordinates with patent attorneys to develop comprehensive IP strategies that align regulatory and intellectual property timelines. We also advise on trade secret protection for know-how, manufacturing processes, and proprietary formulations.

Robust compliance programs are essential for pharmaceutical companies operating in Hungary's highly regulated environment. Our pharmaceutical lawyers design and implement comprehensive compliance programs tailored to our clients' business models, covering interactions with healthcare professionals, promotional practices, transparency reporting, and pharmacovigilance obligations.

We provide compliance training to commercial teams, medical affairs personnel, and senior management on Hungarian pharmaceutical regulations, anti-corruption laws, and industry codes of conduct. Our training programs are practical and role-specific, enabling personnel to make compliant decisions in real-world business situations.

When compliance concerns arise, we conduct internal investigations that preserve legal privilege while thoroughly examining potential violations. We work with companies to implement corrective actions, engage with regulatory authorities when necessary, and strengthen systems to prevent recurrence.

Whether you are launching innovative pharmaceuticals, seeking marketing authorization for generics or biosimilars, establishing commercial operations, or navigating reimbursement negotiations, Jalsovszky's pharmaceutical law Hungary practice provides the comprehensive legal support you need. Contact our pharmaceutical lawyers today to discuss how we can support your business objectives in the Hungarian pharmaceutical market.